Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Scientia, Dipòsit d’...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
versions View all 2 versions
addClaim

Tractament de l’espondilitis anquilosant activa

Authors: Programa d'Harmonització Farmacoterapèutica;

Tractament de l’espondilitis anquilosant activa

Abstract

L’espondilitis anquilosant (EA) és una malaltia inclosa dins el grup de les espondiloartritis axials. Es tracta d’una malaltia inflamatòria potencialment incapacitant, que habitualment es manifesta en forma de dolor en la columna vertebral, tot i que pot anar acompanyada de símptomes articulars extraespinals i d’altres símptomes extraarticulars (psoriasi, uveïtis, etc). Es presenta típicament en pacients joves (20-30 anys), amb predomini masculí (70 %). El tractament inicial per l’EA inclou mesures no farmacològiques i tractament amb antiinflamatoris no esteroidals (AINE) a dosis màximes. En pacients amb resposta inadequada o intolerància als AINE, es recomana l’ús de fàrmacs antireumàtics modificadors de la malaltia biològics (FAMMb) o sintètics dirigits (FAMMsd). L’avaluació d’aquests tractaments es va dur a terme entre els anys 2018 i 2023 en el marc del Programa d’Harmonització Farmacoterapèutica (PHF) que n’ha establert les recomanacions d’ús, així com els criteris de resposta i discontinuació.

Espondilitis anquilosante; Antiinflamatorios no esteroidales (AINE); Antirreumáticos modificadores de la enfermedad biológicos (FAMMb) Antirreumáticos modificadores de la enfermedad sintéticos dirigidos (FAMMsd); Adalimumab

Espondilitis anquilosant; Antiinflamatoris no esteroidals (AINE); Antireumàtics modificadors de la malaltia biològics (FAMMb), antireumàtics modificadors de la malaltia sintètics dirigits (FAMMsd); Adalimumab

Ankylosing spondylitis; Non-steroidal anti-inflammatory drugs (NSAIDs); Biologic disease-modifying antirheumatic drugs (DAMMb); Targeted synthetic disease-modifying antirheumatic drugs (DAMMsd); Adalimumab

Keywords

Other subheadings::Other subheadings::Other subheadings::/drug therapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::desarrollo de medicamentos::evaluación de medicamentos, Antireumàtics, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Medicaments - Assaigs clínics, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Drug Development::Drug Evaluation, ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculoesqueléticas::artropatías::enfermedades musculoesqueléticas::artropatías::artritis::espondiloartritis::espondiloartropatías::espondilitis anquilosante, DISEASES::Musculoskeletal Diseases::Musculoskeletal Diseases::Joint Diseases::Musculoskeletal Diseases::Joint Diseases::Arthritis::Spondylarthritis::Spondylarthropathies::Spondylitis, Ankylosing, Espondiloartritis anquilosant - Tractament

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green